Compare · ATLN vs PKI
ATLN vs PKI
Side-by-side comparison of Atlantic International Corp. (ATLN) and PerkinElmer Inc. (PKI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ATLN and PKI operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- PKI is the larger of the two at $21.38B, about 292.2x ATLN ($73.2M).
- ATLN has hit the wire 11 times in the past 4 weeks while PKI has been quiet.
- PKI has more recent analyst coverage (17 ratings vs 0 for ATLN).
- Company
- Atlantic International Corp.
- PerkinElmer Inc.
- Price
- $0.90-5.48%
- $115.23-0.88%
- Market cap
- $73.2M
- $21.38B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- News (4w)
- 11
- 0
- Recent ratings
- 0
- 17
PerkinElmer Inc.
PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Latest ATLN
- Circle8 Awarded Two $20 Million Dutch Public Sector Contract Extensions, Demonstrating Positive Commercial Momentum Across the Public Sector
- Chairman & CEO Franke Guus Paul Wilhelm sold $308,783 worth of shares (308,783 units at $1.00), decreasing direct ownership by 2% to 12,207,287 units (SEC Form 4)
- SEC Form 424B3 filed by Atlantic International Corp.
- Atlantic International's Circle8 Awarded $175 Million Contract Extension From the Dutch Ministry Of Infrastructure (Rijkswaterstaat)
- Atlantic International Relaunches As Circle8, Reflecting Its Evolution Into A Global Technology and Workforce Solutions Platform
- Atlantic International Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Atlantic International Corp Regains Compliance With Nasdaq Listing Requirements
- SEC Form 424B3 filed by Atlantic International Corp.
- Atlantic International’s Circle8 Secures Minimum $52 Million Government Contract Award
- Atlantic International Reports Record First Quarter 2026 Revenue of $249.9 Million
Latest PKI
- Gonzales Anita covered exercise/tax liability with 119 shares, decreasing direct ownership by 3% to 3,591 units (SEC Form 4)
- Krakowiak Maxwell covered exercise/tax liability with 85 shares, decreasing direct ownership by 1% to 7,117 units (SEC Form 4)
- Klobuchar Michael A was granted 481 shares (SEC Form 4)
- Vandebroek Sophie V. was granted 481 shares (SEC Form 4)
- SEC Form SC 13G/A filed by PerkinElmer Inc. (Amendment)
- SEC Form SC 13G/A filed by PerkinElmer Inc. (Amendment)
- SEC Form SC 13G/A filed by PerkinElmer Inc. (Amendment)
- SEC Form SC 13G/A filed by PerkinElmer Inc. (Amendment)
- Singh Prahlad R. exercised 57,039 shares at a strike of $76.83, sold $2,212,480 worth of shares (21,217 units at $104.28) and covered exercise/tax liability with 15,424 shares, increasing direct ownership by 25% to 103,414 units (SEC Form 4)
- Victor Miriame exercised 2,408 shares at a strike of $105.62 and covered exercise/tax liability with 1,030 shares, increasing direct ownership by 15% to 10,470 units (SEC Form 4)